Still in the game
Share this:
In 2015, ESPN reporter Holly Row was diagnosed with desmoplastic melanoma, a rare, fast-spreading form of skin cancer. After a first surgery, she enrolled in a UCLA clinical trial led by Dr. Antoni Ribas testing a new approach for advanced melanoma in which participants took the drug Keytruda (pembrolizumab) in combination with another immunotherapy drug or with a placebo.
Over a two-year period, Rowe flew to Los Angeles every 21 days for intravenous infusions that successfully led to her tumors shrinking significantly. Within three months of starting her treatment, the tumors in her lung had started to shrink, and by the end of therapy, the largest tumor had decreased in diameter from 21 millimeters to 3 millimeters.
Today, the veteran reporter continues to visit her team at the UCLA Jonsson Comprehensive Cancer Center for regular checkups. Throughout her journey, she continued to offer sideline analysis and conduct interviews with coaches and athletes for ESPN. She also openly shared the ups and downs of her treatment, receiving support from many fans and inspiring others with cancer along the way.
Read her inspirational story in the latest issue of Cancer Today magazine.
Related Posts
UCLA Health experts weigh in on what they hope to see as the new president takes office
Knowing our family health history can help us fight this rare disease for men
In 2020, UCLA’s Cancer Center developed treatments for liver, breast, prostate and lung cancer
Recent Posts
UCLA Health experts weigh in on what they hope to see as the new president takes office
Martin Luther King, Jr. Community Hospital and UCLA Health have vowed to fulfill a promise made in the wake of the Watts Rebellion
Thank you to the Blood and Platelet Center on Gayle for always providing welcoming and experienced service! I know I am in good hands. By: Elizabeth [...]